---
title: "Elevance Health Q3 2026 net income rises 13% year over year to $1.34 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302542349.md"
description: "Elevance Health reported a 13% year-over-year increase in Q3 2026 net income to $1.34 billion, with diluted earnings rising 18% to $6.27 per share. Operating revenue reached $50.44 billion, driven by higher premium yields and CarelonRx growth. However, Health Benefits operating gain declined 27% to $436 million due to strategic investments. The company maintains a full-year 2026 outlook of at least $22 per share in diluted earnings."
datetime: "2026-10-21T10:04:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302542349.md)
  - [en](https://longbridge.com/en/news/302542349.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302542349.md)
generator: "portal-rs"
---

# Elevance Health Q3 2026 net income rises 13% year over year to $1.34 billion

-   Elevance Health’s third-quarter 2026 diluted earnings rose 18% year over year to $6.27 per share. \* Operating revenue increased year over year to $50.44 billion, supported by higher premium yields, CarelonRx product revenue and service fees. \* Health Benefits operating gain fell 27% year over year to $436 million, reflecting targeted investments supporting its long-term operating model. \* The full-year 2026 outlook calls for diluted earnings of at least $22 per share. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elevance Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261020437030) on October 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)

## Related News & Research

- [Is Elevance Health (ELV) Still Undervalued Following Strong Earnings And Higher 2026 Guidance?](https://longbridge.com/en/news/302983253.md)
- [ELV: Q3 outperformance lifts 2026 guidance; long-term adjusted EPS growth target remains 12%](https://longbridge.com/en/news/302542475.md)
- [Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance | ELV Stock News](https://longbridge.com/en/news/302545860.md)
- [Elevance Health, Inc. $ELV Shares Acquired by Robeco Institutional Asset Management B.V.](https://longbridge.com/en/news/302684364.md)
- [Elevance Health, Inc. $ELV Stock Position Cut by Vontobel Holding Ltd.](https://longbridge.com/en/news/302257360.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**